DAVIS, Calif., June 11, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI) (Nasdaq: MBII ) today announced the closing of its previously announced offering of 5,175,000 shares of its common stock at a price to the public of $9.50 per share, which included 600,000 shares sold by an existing stockholder, Syngenta Ventures Pte. LTD., and 675,000 shares issued by MBI upon the exercise in full of the underwriters' option to purchase additional shares. The net proceeds the company will receive from this offering will be approximately $40.0 million, after deducting estimated underwriting discounts and commissions and estimated offering expenses. The Company will not receive any proceeds from the sale of shares by the selling stockholder.
Jefferies LLC and Piper Jaffray & Co. acted as lead joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated, Robert W. Baird & Co. Incorporated and Roth Capital Partners, LLC were co-managers for the offering.
The offering will be made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, at 520 Madison Avenue, New York, New York, 10022, or by calling (877) 547-6340, or by emailing Prospectus_Department@Jefferies.com , and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com .
A registration statement related to these securities has been filed with and declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor Contact: The Blueshirt Group David Niederman +1-415-489-2189
